Abstract

PurposeIntravitreal anti-VEGF injection (IVI) is administered before vitrectomy to assist management of proliferative diabetic retinopathy (PDR)-related complications. In the clinical setting, retinal surgeons determine the use of preoperative IVI based on individual criteria. In this study, we investigated factors related to the potential bias of retinal surgeons in using IVI prior to vitrectomy for PDR-related complications, and evaluated the real-world outcomes of surgeon-determined preoperative IVI.MethodsMedical records of 409 eyes of 409 patients who underwent 25-gauge vitrectomy for PDR complications at seven Japanese centers (22 surgeons) were retrospectively reviewed. Ocular factors, demographic and general clinical factors, surgical procedures, and postoperative complications were compared between IVI group (patients who received preoperative IVI; 87 eyes, 21.3%) and non-IVI group (patients who did not receive preoperative IVI; 322 eyes, 78.7%). In addition, baseline HbA1c in IVI group and non-IVI group was compared between eyes with and without postoperative complications.ResultsAt baseline, IVI group was younger (P<0.001), had shorter duration of diabetes treatment (P = 0.045), and higher frequencies of neovascular glaucoma [NVG] (P<0.001) and tractional retinal detachment [TRD] (P<0.001) compared to non-IVI group. Although IVI group had higher frequencies of intraoperative retinal break and tamponade procedure, there were no significant differences in postoperative complications and additional treatments between two groups. Baseline HbA1c levels were also not correlated with postoperative complications of VH, NVG, and RD both in IVI group and non-IVI group. Logistic regression analysis identified age (P<0.001, odds ratio [OR] 0.95), presence of NVG (P<0.001, OR 20.2), and presence of TRD (P = 0.0014, OR 2.44) as preoperative factors in favor of IVI.ConclusionsIn this multicenter real-world clinical study, younger age and presence of NVG and TRD were identified as potential biases in using IVI before vitrectomy for PDR complications. Eyes that received preoperative IVI had more intraoperative retinal breaks requiring tamponade than eyes not receiving IVI, but postoperative outcome was not different between the two groups.

Highlights

  • Proliferative diabetic retinopathy (PDR) features retinal ischemia, neovascularization, and fibrous proliferation, and is one of the most common diseases leading to blindness worldwide [1]

  • Logistic regression analysis identified age (P

  • We investigated factors related to the potential bias of retinal surgeons in using IVI before vitrectomy for eyes with PDR complications, and evaluated the real-world outcomes of using preoperative IVI determined by surgeons

Read more

Summary

Introduction

Proliferative diabetic retinopathy (PDR) features retinal ischemia, neovascularization, and fibrous proliferation, and is one of the most common diseases leading to blindness worldwide [1]. Pars plana vitrectomy (PPV) is generally used for complications of PDR, which include vitreous hemorrhage (VH) and tractional retinal detachment (TRD) [2]. Since 2007, the use of intravitreal anti-VEGF injection (IVI) has greatly expanded as a treatment for retinal ischemic diseases including PDR [10], and IVI was administered before PPV to assist the management of PDR-related complications [11,12,13]. Retinal surgeons determine the use of preoperative IVI for eyes with PDR-related complications based on individual criteria. We investigated factors related to the potential bias of retinal surgeons in using IVI before vitrectomy for eyes with PDR complications, and evaluated the real-world outcomes of using preoperative IVI determined by surgeons

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call